{
    "clinical_study": {
        "@rank": "136359", 
        "arm_group": [
            {
                "arm_group_label": "Danhong Injection", 
                "arm_group_type": "Experimental", 
                "description": "Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days."
            }
        ], 
        "brief_summary": {
            "textblock": "Research topic.\n\n        -  A clinical trial of Danhong injection in treating acute ischemic stroke .\n\n      Research purpose.\n\n      - To evaluate the efficacy and safety of Danhong injection in treating acute ischemic stroke\n      by a randomized, double-blind, multi-center, placebo-controlled clinical trial.\n\n      Research design.\n\n      - A randomized, double-blind, multi-center, placebo-controlled clinical trial.\n\n      Subject crowd.\n\n      - Accord with standard of western medicine diagnosis of acute cerebral infarction, stroke\n      and blood stasis type of traditional Chinese medicine syndrome differentiation.\n\n      Sample size. - Total sample size of 320 patients, experimental group, control group is equal\n      to 1 to 1.\n\n      Interim analysis.\n\n      - Interim analysis will be performed when the total number of included patients up to half\n      of the sample size ,160 cases, and according to the interim analysis results to estimate the\n      sample size and adjust the project adaptively.\n\n      Course of treatment.\n\n      - 10 days.\n\n      Research endpoint.\n\n      - The 90th day after the medication for the first time.\n\n      Observation index.\n\n        1. General condition; the physical and chemical inspection related;\n\n        2. Efficacy check : mRS, BI, NIHSS;\n\n        3. Safety check: blood routine, urine routine, stool OB, liver function(ALT\u3001AST), renal\n           function (BUN, Cr), coagulation four indices\uff08PT\u3001APTT\u3001TT\u3001FIB), electrocardiogram.\n\n      Efficacy evaluation. 1. The main efficacy index: a. Percentage comparisons of two group\n      patients of modified Rankin 0-2 grades on the 90th day.\n\n      Statistical analysis technique.\n\n      - Statistical analysis using SAS 9.2 system, all the statistical test adopted bilateral\n      inspection, P value less than or equal to 0.05 will be considered a statistically\n      significant difference."
        }, 
        "brief_title": "A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Research topic. - A clinical trial of Danhong injection in treating acute ischemic stroke .\n\n      Research purpose.\n\n        -  To evaluate the efficacy and safety of Danhong injection in treating acute ischemic\n           stroke by a randomized, double-blind, multi-center, placebo-controlled clinical trial.\n\n      Research design. - A randomized, double-blind, multi-center, placebo-controlled clinical\n      trial.\n\n      Subject crowd. - Accord with standard of western medicine diagnosis of acute cerebral\n      infarction, stroke and blood stasis type of traditional Chinese medicine syndrome\n      differentiation.\n\n      Sample size.\n\n      - Total sample size of 320 patients, experimental group, control group is equal to 1 to 1.\n\n      Interim analysis.\n\n      - Interim analysis will be performed when the total number of included patients up to half\n      of the sample size ,160 cases, and according to the interim analysis results to estimate the\n      sample size and adjust the project adaptively.\n\n      Inclusion criteria.\n\n        1. Accord with the diagnostic criteria of cerebral infarction of \"Guide of diagnosis and\n           treatment of acute ischemic stroke in China\" in 2010, and in the acute stage;\n\n        2. Accord with the stroke and blood stasis type;\n\n        3. Onset of acute ischemic stroke within 72 hours;\n\n        4. NIHSS grade \u2265 4;\n\n        5. Age \u2265 18;\n\n        6. signed the inform consent form.\n\n      Exclusion criteria.\n\n        1. Diagnosed with bleeding or other pathological brain disorders according to CT or MRI at\n           baseline , such as vascular malformation, tumor, abscess or other common non ischemic\n           cerebral disease (for multiple sclerosis);\n\n        2. Patients with hrombolysis or endovascular treatment;\n\n        3. Allergic constitution; the test drug allergy or its ingredients or elements allergy;\n\n        4. With severe liver function damage(ALT and AST level more than 1.5 times higher than\n           normal);\n\n        5. With severe renal impairment (more than 1.5 times higher than normal amount of serum\n           creatinine);\n\n        6. With severe cardiac insufficiency (cardiac function rating level III above);\n\n        7. Disabled patients of law (blind, deaf, dumb, mental retardation, mental disorder and\n           physical disabilities caused by other reasons which affects the nerve function defect\n           evaluation);\n\n        8. With bleeding tendency or had serious bleeding within 3 months;\n\n        9. Doubted or had alcohol and drug abuse history; Or who will lower the possibilities of\n           enrollment or complicate the enrollment according to the investigaters' judgement;\n\n       10. Menstrual period women, pregnant women and lactating women, pregnancy test positive or\n           recent family planning;\n\n       11. Who being in other clinical trials or had finished other clinical trials within 3\n           months.\n\n           Dosage regimen.\n\n           1. Experimental group: Danhong injection 40 ml add 250 ml of 0.9% sodium chloride\n           solution, injection intravenous drip, 1 time a day, for 10 days; 2. Control group :\n           0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution,\n           injection intravenous drip, 1 time a day, for 10 days.\n\n           Course of treatment.\n\n             -  10 days.\n\n           Research endpoint.\n\n           - The 90th day after the medication for the first time.\n\n           Observation index.\n\n        1. General condition; the physical and chemical inspection related;\n\n        2. Efficacy check : mRS, BI, NIHSS;\n\n        3. Safety check: blood routine, urine routine, stool OB, liver function(ALT\u3001AST), renal\n           function (BUN, Cr), coagulation four indices\uff08PT\u3001APTT\u3001TT\u3001FIB), electrocardiogram.\n\n      Observation point.\n\n        1. The physical and chemical inspection related and electrocardiogram observed at the\n           enrollment time;\n\n        2. General condition and efficacy index observed on the 10th ,90th after the medication\n           for the first time;\n\n        3. Safety index observed on the 10th after the medication for the first time.\n\n      Efficacy evaluation.\n\n        1. The main efficacy index:\n\n             1. Percentage comparisons of two group patients of modified Rankin 0-2 grades on the\n                90th day.\n\n        2. The secondary efficacy index:\n\n             1. Mortality comparisons of two group patients on the 90th day;\n\n             2. Percentage comparisons of two group patients of BI\u226575 on the 90th day;\n\n             3. NIHSS difference comparisons of two group on the 90th day;\n\n             4. The proportion of new vascular events within 3 months (Ischemic stroke/hemorrhagic\n                stroke/TIA/MI/vascular death).\n\n      Safety evaluation.\n\n        1. All-Cause mortality within 90 days :the death toll of all cause within 90 days/ the\n           total number of each group \u00d7 100%;\n\n        2. Incidence of serious bleeding events (GUSTO definition, appendix 4), including fatal\n           bleeding and symptomatic intracranial bleeding;\n\n        3. Incidence of moderate bleeding events (GUSTO definition, appendix 4);\n\n        4. Adverse events and serious adverse events reported by investigaters.\n\n      Statistical analysis technique.\n\n      - Statistical analysis using SAS 9.2 system, all the statistical test adopted bilateral\n      inspection, P value less than or equal to 0.05 will be considered a statistically\n      significant difference."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Accord with the diagnostic criteria of cerebral infarction of \"Guide of diagnosis and\n             treatment of acute ischemic stroke in China\" in 2010, and in the acute stage;\n\n          -  Accord with the stroke and blood stasis type;\n\n          -  Onset of acute ischemic stroke within 72 hours;\n\n          -  NIHSS grade \u2265 4;\n\n          -  Age \u2265 18;\n\n          -  signed the inform consent form.\n\n        Exclusion Criteria:\n\n          -  Diagnosed with bleeding or other pathological brain disorders according to CT or MRI\n             at baseline , such as vascular malformation, tumor, abscess or other common non\n             ischemic cerebral disease (for multiple sclerosis);\n\n          -  Patients with hrombolysis or endovascular treatment;\n\n          -  Allergic constitution; the test drug allergy or its ingredients or elements allergy;\n\n          -  With severe liver function damage(ALT and AST level more than 1.5 times higher than\n             normal);\n\n          -  With severe renal impairment (more than 1.5 times higher than normal amount of serum\n             creatinine);\n\n          -  With severe cardiac insufficiency (cardiac function rating level III above)\n\n          -  Disabled patients of law (blind, deaf, dumb, mental retardation, mental disorder and\n             physical disabilities caused by other reasons which affects the nerve function defect\n             evaluation);\n\n          -  With bleeding tendency or had serious bleeding within 3 months;\n\n          -  Doubted or had alcohol and drug abuse history; Or who will lower the possibilities of\n             enrollment or complicate the enrollment according to the investigaters' judgement;\n\n          -  Menstrual period women, pregnant women and lactating women, pregnancy test positive\n             or recent family planning;\n\n          -  Who being in other clinical trials or had finished other clinical trials within 3\n             months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152280", 
            "org_study_id": "V2.0"
        }, 
        "intervention": [
            {
                "arm_group_label": "Danhong Injection", 
                "description": "Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.", 
                "intervention_name": "Danhong Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "description": "0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;", 
                "intervention_name": "Normal Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 30, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke", 
        "overall_official": {
            "affiliation": "Traditional Chinese medicine department of Zhongshan Hospital", 
            "last_name": "Fang D Cai, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percentage comparisons of two groups of patients on the modified Rankin Scale 0-2 grades on the 90th day.", 
            "measure": "Percentage comparisons of two groups of  patients on the modified Rankin Scale 0-2 grades on the 90th day.", 
            "safety_issue": "No", 
            "time_frame": "0-90 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152280"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Beijing Bozhiyin T&S Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Bozhiyin T&S Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}